Identification and characterization of an alternative cancer-derived PD-L1 splice variant

Nadia B. Hassounah, Venkat S. Malladi, Yi Huang, Samuel S. Freeman, Ellen M. Beauchamp, Shohei Koyama, Nicholas Souders, Sunil Martin, Glenn Dranoff, Kwok Kin Wong, Chandra S. Pedamallu, Peter S. Hammerman, Esra A. Akbay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Therapeutic blockade of the PD-1/PD-L1 axis is recognized as an effective treatment for numerous cancer types. However, only a subset of patients respond to this treatment, warranting a greater understanding of the biological mechanisms driving immune evasion via PD-1/PD-L1 signaling and other T-cell suppressive pathways. We previously identified a head and neck squamous cell carcinoma with human papillomavirus integration in the PD-L1 locus upstream of the transmembrane domain-encoding region, suggesting expression of a truncated form of PD-L1 (Parfenov et al., Proc Natl Acad Sci USA111(43):15544–15549, 2014). In this study, we extended this observation by performing a computational analysis of 33 other cancer types as well as human cancer cell lines, and identified additional PD-L1 isoforms with an exon 4 enrichment expressed in 20 cancers and human cancer cell lines. We demonstrate that cancer cell lines with high expression levels of exon 4-enriched PD-L1 generate a secreted form of PD-L1. Further biochemical studies of exon 4-enriched PD-L1 demonstrated that this form is secreted and maintains the capacity to bind PD-1 as well as to serve as a negative regulator on T cell function, as measured by inhibition of IL-2 and IFNg secretion. Overall, we have demonstrated that truncated forms of PD-L1 exist in numerous cancer types, and have validated that truncated PD-L1 can be secreted and negatively regulate T cell function.

Original languageEnglish (US)
Pages (from-to)407-420
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume68
Issue number3
DOIs
StatePublished - Mar 13 2019

Fingerprint

Neoplasms
Exons
T-Lymphocytes
Cell Line
Immune Evasion
Interleukin-2
Protein Isoforms
Therapeutics

Keywords

  • Cancer immunology
  • HPV
  • PD-L1
  • Secreted PD-L1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Identification and characterization of an alternative cancer-derived PD-L1 splice variant. / Hassounah, Nadia B.; Malladi, Venkat S.; Huang, Yi; Freeman, Samuel S.; Beauchamp, Ellen M.; Koyama, Shohei; Souders, Nicholas; Martin, Sunil; Dranoff, Glenn; Wong, Kwok Kin; Pedamallu, Chandra S.; Hammerman, Peter S.; Akbay, Esra A.

In: Cancer Immunology, Immunotherapy, Vol. 68, No. 3, 13.03.2019, p. 407-420.

Research output: Contribution to journalArticle

Hassounah, NB, Malladi, VS, Huang, Y, Freeman, SS, Beauchamp, EM, Koyama, S, Souders, N, Martin, S, Dranoff, G, Wong, KK, Pedamallu, CS, Hammerman, PS & Akbay, EA 2019, 'Identification and characterization of an alternative cancer-derived PD-L1 splice variant', Cancer Immunology, Immunotherapy, vol. 68, no. 3, pp. 407-420. https://doi.org/10.1007/s00262-018-2284-z
Hassounah, Nadia B. ; Malladi, Venkat S. ; Huang, Yi ; Freeman, Samuel S. ; Beauchamp, Ellen M. ; Koyama, Shohei ; Souders, Nicholas ; Martin, Sunil ; Dranoff, Glenn ; Wong, Kwok Kin ; Pedamallu, Chandra S. ; Hammerman, Peter S. ; Akbay, Esra A. / Identification and characterization of an alternative cancer-derived PD-L1 splice variant. In: Cancer Immunology, Immunotherapy. 2019 ; Vol. 68, No. 3. pp. 407-420.
@article{fa809d61cf4e4472a720ebe33967c83b,
title = "Identification and characterization of an alternative cancer-derived PD-L1 splice variant",
abstract = "Therapeutic blockade of the PD-1/PD-L1 axis is recognized as an effective treatment for numerous cancer types. However, only a subset of patients respond to this treatment, warranting a greater understanding of the biological mechanisms driving immune evasion via PD-1/PD-L1 signaling and other T-cell suppressive pathways. We previously identified a head and neck squamous cell carcinoma with human papillomavirus integration in the PD-L1 locus upstream of the transmembrane domain-encoding region, suggesting expression of a truncated form of PD-L1 (Parfenov et al., Proc Natl Acad Sci USA111(43):15544–15549, 2014). In this study, we extended this observation by performing a computational analysis of 33 other cancer types as well as human cancer cell lines, and identified additional PD-L1 isoforms with an exon 4 enrichment expressed in 20 cancers and human cancer cell lines. We demonstrate that cancer cell lines with high expression levels of exon 4-enriched PD-L1 generate a secreted form of PD-L1. Further biochemical studies of exon 4-enriched PD-L1 demonstrated that this form is secreted and maintains the capacity to bind PD-1 as well as to serve as a negative regulator on T cell function, as measured by inhibition of IL-2 and IFNg secretion. Overall, we have demonstrated that truncated forms of PD-L1 exist in numerous cancer types, and have validated that truncated PD-L1 can be secreted and negatively regulate T cell function.",
keywords = "Cancer immunology, HPV, PD-L1, Secreted PD-L1",
author = "Hassounah, {Nadia B.} and Malladi, {Venkat S.} and Yi Huang and Freeman, {Samuel S.} and Beauchamp, {Ellen M.} and Shohei Koyama and Nicholas Souders and Sunil Martin and Glenn Dranoff and Wong, {Kwok Kin} and Pedamallu, {Chandra S.} and Hammerman, {Peter S.} and Akbay, {Esra A.}",
year = "2019",
month = "3",
day = "13",
doi = "10.1007/s00262-018-2284-z",
language = "English (US)",
volume = "68",
pages = "407--420",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Identification and characterization of an alternative cancer-derived PD-L1 splice variant

AU - Hassounah, Nadia B.

AU - Malladi, Venkat S.

AU - Huang, Yi

AU - Freeman, Samuel S.

AU - Beauchamp, Ellen M.

AU - Koyama, Shohei

AU - Souders, Nicholas

AU - Martin, Sunil

AU - Dranoff, Glenn

AU - Wong, Kwok Kin

AU - Pedamallu, Chandra S.

AU - Hammerman, Peter S.

AU - Akbay, Esra A.

PY - 2019/3/13

Y1 - 2019/3/13

N2 - Therapeutic blockade of the PD-1/PD-L1 axis is recognized as an effective treatment for numerous cancer types. However, only a subset of patients respond to this treatment, warranting a greater understanding of the biological mechanisms driving immune evasion via PD-1/PD-L1 signaling and other T-cell suppressive pathways. We previously identified a head and neck squamous cell carcinoma with human papillomavirus integration in the PD-L1 locus upstream of the transmembrane domain-encoding region, suggesting expression of a truncated form of PD-L1 (Parfenov et al., Proc Natl Acad Sci USA111(43):15544–15549, 2014). In this study, we extended this observation by performing a computational analysis of 33 other cancer types as well as human cancer cell lines, and identified additional PD-L1 isoforms with an exon 4 enrichment expressed in 20 cancers and human cancer cell lines. We demonstrate that cancer cell lines with high expression levels of exon 4-enriched PD-L1 generate a secreted form of PD-L1. Further biochemical studies of exon 4-enriched PD-L1 demonstrated that this form is secreted and maintains the capacity to bind PD-1 as well as to serve as a negative regulator on T cell function, as measured by inhibition of IL-2 and IFNg secretion. Overall, we have demonstrated that truncated forms of PD-L1 exist in numerous cancer types, and have validated that truncated PD-L1 can be secreted and negatively regulate T cell function.

AB - Therapeutic blockade of the PD-1/PD-L1 axis is recognized as an effective treatment for numerous cancer types. However, only a subset of patients respond to this treatment, warranting a greater understanding of the biological mechanisms driving immune evasion via PD-1/PD-L1 signaling and other T-cell suppressive pathways. We previously identified a head and neck squamous cell carcinoma with human papillomavirus integration in the PD-L1 locus upstream of the transmembrane domain-encoding region, suggesting expression of a truncated form of PD-L1 (Parfenov et al., Proc Natl Acad Sci USA111(43):15544–15549, 2014). In this study, we extended this observation by performing a computational analysis of 33 other cancer types as well as human cancer cell lines, and identified additional PD-L1 isoforms with an exon 4 enrichment expressed in 20 cancers and human cancer cell lines. We demonstrate that cancer cell lines with high expression levels of exon 4-enriched PD-L1 generate a secreted form of PD-L1. Further biochemical studies of exon 4-enriched PD-L1 demonstrated that this form is secreted and maintains the capacity to bind PD-1 as well as to serve as a negative regulator on T cell function, as measured by inhibition of IL-2 and IFNg secretion. Overall, we have demonstrated that truncated forms of PD-L1 exist in numerous cancer types, and have validated that truncated PD-L1 can be secreted and negatively regulate T cell function.

KW - Cancer immunology

KW - HPV

KW - PD-L1

KW - Secreted PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85063284063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063284063&partnerID=8YFLogxK

U2 - 10.1007/s00262-018-2284-z

DO - 10.1007/s00262-018-2284-z

M3 - Article

C2 - 30564890

AN - SCOPUS:85063284063

VL - 68

SP - 407

EP - 420

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -